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Periprosthetic Joint Infection Increases the Risk
of One-Year Mortality
Benjamin Zmistowski, BS, Joseph A. Karam, MD, Joel B. Durinka, MD, David S. Casper, BS, and Javad Parvizi, MD, FRCS
Investigation performed at the Rothman Institute at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Background: Periprosthetic joint infection continues to potentially complicate an otherwise successful joint replace-
ment. The treatment of this infection often requires multiple surgical procedures associated with increased complications
and morbidity. This study examined the relationship between periprosthetic joint infection and mortality and aimed to
determine the effect of periprosthetic joint infection on mortality and any predictors of mortality in patients with peri-
prosthetic joint infection.
Methods: Four hundred and thirty-six patients with at least one surgical intervention secondary to confirmed peri-
prosthetic joint infection were compared with 2342 patients undergoing revision arthroplasty for aseptic failure.
The incidence of mortality at thirty days, ninety days, one year, two years, and five years after surgery was assessed.
Multivariate analysis was used to assess periprosthetic joint infection as an independent predictor of mortality. In
the periprosthetic joint infection population, variables investigated as potential risk factors for mortality were
evaluated.
Results: Mortality was significantly greater (p < 0.001) in patients with periprosthetic joint infection compared with those
undergoing aseptic revision arthroplasty at ninety days (3.7% versus 0.8%), one year (10.6% versus 2.0%), two years
(13.6% versus 3.9%), and five years (25.9% versus 12.9%). After controlling for age, sex, ethnicity, number of procedures,
involved joint, bodymass index, and Charlson Comorbidity Index, revision arthroplasty for periprosthetic joint infection was
associated with a fivefold increase in mortality compared with revision arthroplasty for aseptic failures. In the peri-
prosthetic joint infection population, independent predictors of mortality included increasing age, higher Charlson Co-
morbidity Index, history of stroke, polymicrobial infections, and cardiac disease.
Conclusions: Although it is well known that periprosthetic joint infection is a devastating complication that severely
limits joint function and is consistently difficult to eradicate, surgeons must also be cognizant of the systemic impact of
periprosthetic joint infection and its major influence on fatal outcome in patients.
Level of Evidence: Prognostic Level II. See Instructions for Authors for a complete description of levels of evidence.
T
otal joint arthroplasty is currently one of the most
frequently performed and most successful surgical
procedures, greatly improving patient quality of life
and functional status1,2. Many authors have demonstrated
lower mortality rates for patients undergoing total joint ar-
throplasty compared with those for the general population3-8.
Although complications following total joint arthroplasty are
infrequent, their existence continues to be a cause for concern9-12.
Periprosthetic joint infection is one particularly challenging
complication of total joint arthroplasty. Substantial efforts have
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been made to prevent this complication by implementing
numerous strategies that include antibiotic prophylaxis, patient
risk stratification, detection and treatment of Staphylococcus
aureus colonization, and clean operating room environment,
among others11,13,14. Despite the introduction of these meth-
ods, the risk of infection after total joint arthroplasty remains
approximately 1%11,15-17. In recent studies, Bozic et al. observed
that infection was the third most common indication for revi-
sion hip arthroplasty (14.7% of cases) and the most com-
mon cause for failure of total knee arthroplasty (25.2% of
cases)18,19.
The risk factors for developing periprosthetic joint infec-
tion following total joint arthroplasty includemale sex, advanced
age, higher body mass index (BMI), and presence of comorbid-
ities (especially cardiac conditions)11,15,20-25. These factors are also
associated with early mortality following total joint arthro-
plasty24-28, suggesting that periprosthetic joint infection would
be associated with an increased risk of mortality. The disease
process of periprosthetic joint infection itself may also lead to
an increase in mortality, as experienced in other fields, through
the potential development of fatal bacteremia29-31. Additionally,
the need for aggressive and often multiple surgical treatments,
long-term inpatient stays, and long-term use of systemic anti-
biotics to treat periprosthetic joint infection would be expected
to alter life expectancy32-34.
With the projected increase in the numbers of total joint
arthroplasties, specifically revision arthroplasties, the burden of
periprosthetic joint infection is expected to rise15,35. Hence, a
complete understanding of the effect that this disease may have
on quality and longevity of life is important. Therefore, this
study aimed to determine the impact of periprosthetic joint
infection on life expectancy and to identify any factors that
predict increased mortality rates after treatment for periprosthetic
joint infection.
Materials and Methods
After obtaining institutional review board approval, a retrospective studywas undertaken. Patients undergoing revision hip or knee arthroplasty
from January 2000 through March 2010 were identified utilizing the insti-
tutional database. This provided 2955 patients who underwent revision joint
arthroplasty. This sample included 613 (20.7%) who were suspected of
having periprosthetic joint infection. Complete data related to the workup
for periprosthetic joint infection, including erythrocyte sedimentation rate
(ESR) and serum C-reactive protein (CRP) concentration, synovial fluid
analysis and culture, tissue culture, and joint presentation, were collected.
Utilizing these data, a diagnosis of periprosthetic joint infection was con-
firmed or was excluded on the basis of the definition of periprosthetic joint
infection provided by the Musculoskeletal Infection Society
36
. As histolog-
ical analysis is not performed at this institution, the definition was modified
to require a sinus tract, two separate positive cultures with phenotypically
identical organisms, or three of the following: elevated ESR and CRP, elevated
synovial white blood cell count, elevated synovial fluid polymorphonuclear
neutrophil (PMN) percentage, intra-articular purulence, and a single positive
culture. The threshold was 30 mm per hour for ESR, 10 mg per liter for CRP,
3000 cells per microliter for the synovial white blood cell count, and 75% for
the synovial PMN percentage
37-39
. A diagnosis of periprosthetic joint infection
was confirmed in 436 patients, leaving 2342 patients in the aseptic cohort.
TABLE I Comparison of Demographics Between Patients Undergoing Treatment for Periprosthetic Joint Infection and Those Undergoing
Aseptic Revision Arthroplasty
Demographics
Periprosthetic Joint
Infection Group (N = 436)
Aseptic Revision
Group (N = 2342) P Value
Age* (yr) 67.0 (66.4 to 67.5) 66.2 (65.9 to 66.4) 0.22
Knee joint involved† 266 (61.0) 760 (32.5) <0.001
No. of procedures*
In ninety days 1.6 (1.6 to 1.6) 1.1 (1.0 to 1.1) <0.001
In one year 2.2 (1.1 to 2.2) 1.1 (1.0 to 1.1) <0.001
Male patients† 220 (50.5) 959 (40.9) <0.001
Charlson Comorbidity
Index†
<0.001
0 266 (61.0) 1848 (78.9)
1 128 (29.4) 403 (17.2)
2 27 (6.2) 75 (3.2)
‡3 15 (3.4) 16 (0.7)
Ethnicity† <0.001
White 357 (81.9) 1677 (71.6)
Black 47 (10.8) 268 (11.4)
Other 6 (1.4) 34 (1.5)
Missing 26 (6.0) 363 (15.5)
BMI* (kg/m2) 31.7 (31.3 to 32.1) 29.6 (29.4 to 29.8) <0.001
*The values are given as the mean, with the 95% confidence interval in parentheses. †The values are given as the number of patients, with the
percentage in parentheses.
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To ascertain the deceased patients in this cohort, a Social Security
number or other identifiers were used to search the Social Security Death
Index. If the patient had died, the date of death was recorded. Mortality
incidence within thirty days, ninety days, one year, two years, and five years
of admission was calculated. The time until death was calculated as the
amount of time elapsing from the initial surgical intervention for joint
failure (revision) to the date of death. For calculating mortality at thirty
days, ninety days, and one year, the entire cohort was utilized, as the min-
imum time frame from admission to the mortality search was eighteen
months. To maintain a minimum buffer of six months between the desired
follow-up length and the mortality search, the cohort was limited to all
patients with an initial arthroplasty date prior to April 1, 2009, when cal-
culating the two-year death incidence; this provided a minimum of thirty
months between mortality search and admission. Similarly, the cohort was
limited to admissions prior to April 1, 2006, when calculating the five-year
death incidence. Patients undergoing aseptic revision were used as a
control group. If an association between periprosthetic joint infection
and mortality was observed, attempts to further quantify this risk were made
TABLE II Survival Over Varying Time Periods Following Initial Treatment for Periprosthetic Joint Infection Versus Aseptic Failure
for Patients with Available Follow-up for the Maximum Time of the Period
Started Period Alive
Finished
Period Alive
Time Period (Time from Initial Treatment) Septic Aseptic Septic Aseptic
Periprosthetic
Joint Infection
Survival
Aseptic
Survival
Periprosthetic
Joint Infection
Relative Survival* P Value
Time of initial treatment to thirty days 436 2342 433 2328 99.3% 99.4% 99.9% 0.82
Thirty to ninety days 433 2328 420 2322 97.0% 99.7% 97.3% <0.001
Ninety days to one year 420 2322 390 2294 92.9% 98.8% 94.1% <0.001
One to two years 342 2107 332 2067 97.1% 98.1% 99.0% 0.21
Two to five years 214 1407 187 1275 87.4% 90.6% 96.8% 0.14
Time of initial treatment to ninety days 436 2342 420 2322 96.3% 99.2% 97.2% <0.001
Time of initial treatment to one year 436 2342 390 2294 89.5% 98.0% 91.5% <0.001
Time of initial treatment to two years 384 2151 332 2067 86.5% 96.1% 90.4% <0.001
Time of initial treatment to five years f253 1468 187 1275 73.9% 86.9% 87.1% <0.001
*The relative survival for periprosthetic joint infection, the survival attributable to the periprosthetic joint infection diagnosis (after adjusting for the aseptic control),
decreases over time, with the most significant decreases occurring in the first year.
TABLE III Multivariate Logistic Regression Comparing Mortality and Variables for Four Models
Model 1* (N = 2778) Model 2† (N = 2778) Model 3‡ (N = 2778) Model 4§ (N = 2375)
Variables Odds Ratio# P Value** Odds Ratio# P Value** Odds Ratio# P Value** Odds Ratio# P Value**
Periprosthetic joint
infection diagnosis
5.6 (3.7-8.6) <0.001 6.0 (3.9-9.2) <0.001 5.6 (3.4-9.2) <0.001 5.9 (3.5-10.2) <0.001
Age 1.1 (1.1-1.1) <0.001 1.1 (1.1-1.1) <0.001 1.1 (1.1-1.1) <0.001
Male sex 1.7 (1.1-2.7) 0.02 1.6 (1.0-2.6) 0.06
Charlson Comorbidity
Index
1.7 (1.4-2.0) <0.001 1.7 (1.4-2.0) <0.001
Knee joint involved 0.9 (0.6-1.5) 0.69 0.8 (0.5-1.4) 0.43
Procedures in ninety days 0.8 (0.5-1.1) 0.17 0.8 (0.5-1.2) 0.32
Ethnicity NA†† 0.84 NA†† 0.82
Black (versus white) 1.0 (0.5-2.3) 0.96 0.8 (0.4-2.1) 0.76
Other (versus white) 0.3 (0.0-6.5) 0.48 0.4 (0.0-7.6) 0.56
Unknown (versus white) 1.2 (0.6-2.3) 0.59 1.3 (0.6-2.7) 0.51
BMI 1.0 (1.0-1.1) 0.20
*Model 1 compared mortality with periprosthetic joint infection alone. †Model 2 compared mortality with periprosthetic joint infection adjusted for age. ‡Model 3
compared mortality with periprosthetic joint infection adjusted for age, sex, Charlson Comorbidity Index, ethnicity, number of procedures within ninety days of the
original procedure, and knee joint involved. §Model 4 compared mortality with periprosthetic joint infection adjusted for all variables. #The values are given as the odds
ratios, with the 95% confidence intervals in parentheses. **A periprosthetic joint infection diagnosis, age, male sex, and Charlson Comorbidity Index were found to be
significant predictors in the model predicting one-year mortality. ††NA = not applicable.
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by controlling for other potential predictors of mortality. These predictors
included sex, age, ethnicity, number of joint-related procedures, BMI, and
Charlson Comorbidity Index. The Charlson Comorbidity Index provides a
method of quantifying overall health and is predictive of mortality
40
. For this
analysis, the Dartmouth-Manitoba adaptation was used to calculate the
Charlson Comorbidity Index and was not adjusted for age
41
. The number
of joint-related procedures was gathered from the institutional database
and was limited to the total number of procedures performed on a lower-
extremity joint within one year of the initial treatment. The null hypothesis
was that periprosthetic joint infection would not impact mortality in this
cohort.
Another goal of this study was to identify any factors that predicted one-
year mortality in patients with periprosthetic joint infection. Factors investigated
included age, sex, ethnicity, number of procedures, Charlson Comorbidity Index,
specific comorbidities, and infecting organism. Specific comorbidities were related
to cardiac disorder, respiratory disorder, gastrointestinal disorder, neurologic
disorder, or diabetes
42
. Infecting organisms were assessed for each periprosthetic
joint infection admission and were aggregated taxonomically. The null hypoth-
esis was that none of the tested variables would predict mortality in the cohort
treated for periprosthetic joint infection.
To test the null hypotheses, bivariate analysis was performed. This
consisted of the Student t test for continuous variables and the chi-square test
(number of events greater than ten) or Fisher exact test (lower event size) for
categorical variables. Multivariate analysis was then performed to ascertain
independent predictors of the studied outcome if a sufficient event size ex-
isted. Multivariable analysis for the entire cohort was performed with a
logistic regression, including all potential variables in a pseudo-stepwise
manner: first including only periprosthetic joint infection, then including
periprosthetic joint infection and age, then including all variables except
BMI, and finally including all potential predictors of mortality. BMI was
excluded in the third model, as this variable was only available in 2375
(85.5%) of the 2778 cases. Subsequently, multivariable analysis was per-
formed on the periprosthetic joint infection cohort to determine indepen-
dent predictors of mortality in this cohort.
Source of Funding
No external funds were received for the performance of this research.
Results
In this cohort, the incidence of mortality for all patients was0.6% (seventeen of 2778) within thirty days, 1.3% (thirty-six
of 2778) within ninety days, 3.4% (ninety-four of 2778) within
one year, 5.4% (136 of 2535) within two years, and 15.0% (259
of 1721) within five years. Patients with periprosthetic joint
TABLE IV Bivariate Analysis of Potential Predictors of Mortality in the First Year After Treatment for Periprosthetic Joint Infection
Variable First-Year Mortality (N = 46) First-Year Survival (N = 390) Bivariate P Value
Age* (yr) 73.2 (71.7 to 74.7) 66.2 (65.6 to 66.8) <0.001
Male sex† 27 (58.7) 193 (49.5) 0.24
Knee joint involved† 28 (60.9) 238 (61.0) 0.98
No. of procedures*
In ninety days 1.5 (1.3 to 1.6) 1.6 (1.6 to 1.7) 0.26
In one year 1.6 (1.4 to 1.8) 2.2 (2.2 to 2.3) <0.001
Charlson Comorbidity Index† <0.001
0 16 (34.8) 250 (64.1)
1 16 (34.8) 112 (28.7)
2 8 (17.4) 19 (4.9)
‡3 6 (13.0) 9 (2.3)
Ethnicity† 0.46
White 36 (78.3) 321 (82.3)
Black 4 (8.7) 43 (11.0)
Other 1 (2.2) 5 (12.8)
Unknown 5 (10.9) 21 (5.4)
Specific comorbidities†
Diabetes 12 (26.1) 90 (23.1) 0.65
Cardiac disease 25 (54.3) 115 (29.5) <0.001
Chronic obstructive
pulmonary disease
12 (26.1) 46 (11.8) 0.09
Gastrointestinal disorders 4 (8.7) 8 (2.1) 0.03
History of cerebrovascular
accident
9 (19.6) 16 (4.1) <0.001
Renal disease 0 (0) 1 (0.3) 0.11
BMI* (kg/m2) 30.0 (27.2 to 32.8) 31.9 (31.1 to 32.8) 0.16
*The values are given as the mean, with the 95% confidence interval in parentheses. †The values are given as the number of patients, with the
percentage in parentheses.
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infection had similar age, but were more likely male, had ele-
vated age-unadjusted Charlson Comorbidity Index, were more
likely undergoing knee revision arthroplasty, and had a greater
number of joint-related procedures compared with patients un-
dergoing aseptic revision surgery (Table I). Mortality was sig-
nificantly greater (p < 0.001) in patients with periprosthetic joint
infection than in patients undergoing aseptic revision at the
ninety-day, one-year, two-year, and five-year time points (Fig. 1).
When assessing each individual time period, the mortality inci-
dence was significantly greater (p < 0.001) in patients with
periprosthetic joint infection from thirty to ninety days and
from ninety days to one year (Table II). Also, the relative five-
year survival rate in patients with periprosthetic joint infection
was 87.3%. Furthermore, periprosthetic joint infection was a
predictor of one-year mortality when adjusting only for age;
when adjusting for ethnicity, age, sex, number of procedures
within ninety days, joint, and Charlson Comorbidity Index;
and when adjusting for all variables (Table III), including BMI,
rejecting the null hypothesis.
Advanced age (p < 0.001), increased Charlson Comor-
bidity Index (p < 0.001), cardiac disease (p < 0.001), gastro-
intestinal disorders (p = 0.03), and history of cerebrovascular
accident (p < 0.001) were significant predictors of mortality in
patients with periprosthetic joint infection in bivariate analysis
(Table IV). No significant difference in mortality was observed
between patients with hip infections and those with knee in-
fections. Infections caused by gram-negative organisms resulted
in a one-year mortality rate of 19.3% (eleven of fifty-seven)
compared with 9.2% (thirty-five of 379) in periprosthetic joint
infection cases without gram-negative organisms (p = 0.02)
(see Appendix). For major taxonomic groups, multiple trends
were evident, including significantly increased mortality (p =
0.08) in patients who had periprosthetic joint infection due
to methicillin-resistant S. aureus (MRSA) (15.9% [thirteen of
eighty-two]) compared with patients who had periprosthetic
joint infection due to methicillin-sensitive S. aureus (MSSA)
(7.4% [seven of ninety-five]). When performing multivariate
analysis, age, number of surgical procedures in the first year,
Charlson Comorbidity Index, cardiac disease, history of stroke,
and polymicrobial infections were independent predictors of
one-year mortality in patients with periprosthetic joint infec-
tion (Table V).
Fig. 1
Kaplan-Meier survival curve with 95% confidence intervals for five years from first admission for patients undergoing revision arthroplasty.
The analysis is separated into patients undergoing treatment for periprosthetic joint infection or aseptic failure. Vertical marks indicate censoring.
At established time points (thirty days, ninety days, one year, two years, and five years), the mortality incidence in all patients available for analysis
at that time point is displayed. A = patients undergoing aseptic revision, and S = patients undergoing septic revision.
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Discussion
Periprosthetic joint infection remains a major complicationof total joint arthroplasty43. The outcome following treatment
for periprosthetic joint infection ranges from a return to full func-
tion to the possible need for amputation or arthrodesis33,41,44,45.
Of rising concern throughout the joint replacement community
is infection involving MRSA, as it is often resistant to aggressive
treatment, resulting in suboptimal outcome46-49. Additionally, patient
health status has been implicated in predicting the outcome of
periprosthetic joint infection treatment50. This study investi-
gated the impact of periprosthetic joint infection on mortality
and the predictors of mortality in patients with periprosthetic
joint infection.
There was a significant increase in mortality in patients
undergoing surgical intervention for periprosthetic joint in-
fection compared with patients undergoing aseptic revision
arthroplasty. Periprosthetic joint infection increased the risk of
death more than fivefold when controlling for other potential
confounding variables. McGarry et al. reported a fivefold in-
crease in the ninety-daymortality risk after surgical site infection
in an elderly population undergoing various surgical proce-
dures30. This is similar to the fivefold increase in the unadjusted
mortality risk at ninety days found for patients with periprosthetic
joint infection. Interestingly, the effect of periprosthetic joint
infection on mortality is greatest between thirty days and one
year, with no statistical difference in mortality between one and
five years. Despite this, the relative survival rate of patients with
periprosthetic joint infection compared with those requiring
aseptic revision was 87.3% at five years. For comparison, the
five-year relative survival rates for the top five most common
cancers are 99% for prostate cancer, 89% for breast cancer, 16%
for lung and bronchial cancer, 64% for colorectal cancer, and
91% for melanoma51. The effect of periprosthetic joint infec-
tion on patient mortality within thirty days is inconclusive,
possibly stemming from a type-II error or an indication that no
difference exists in the initial insult required in treating peri-
prosthetic joint infection compared with aseptic failure. Other
authors have provided anecdotal evidence of increased mor-
tality in patients receiving treatment for periprosthetic joint
infection52-54. Most recently, Berend et al. reported 4%mortality
within ninety days52. Previously identified risk factors for peri-
prosthetic joint infection include male sex, advanced age, in-
creased BMI, increased number of comorbidities, and knee
arthroplasty, among others11,15,20-23. Many risk factors are also
associated with an increased risk of mortality, implying that the
association between mortality and periprosthetic joint infec-
tion is secondary to poor health status. However, after adjusting
for such factors, periprosthetic joint infection remained a sig-
nificant predictor of mortality, suggesting that the disease
process or the treatment itself contributes to the increased risk
of death.
Independent predictors of first-year mortality were ad-
vanced age, increased Charlson Comorbidity Index, cardiac
disease, and history of cerebrovascular accident. Inmultivariate
analysis, the number of procedures within one year had a pro-
tective effect onmortality. Although surgical intervention carries
the risk of death, the number of procedures was likely protective
because it signaled that patients had a level of health allowing
for repeated surgical intervention. From a microbiological stand-
point, patients with multiple organisms on culture, MRSA, and
gram-negative organisms had increased first-year mortality.
Marculescu and Cantey found that patient age greater than
sixty-five years was an independent risk factor for polymicrobial
periprosthetic joint infection compared with monomicrobial
periprosthetic joint infection, which may account for the mod-
erate increase in mortality55. However, polymicrobial infections
were a predictor of mortality independent of age and overall
TABLE V Multivariate Analysis of Potential Predictors of Mortality
in the First Year After Treatment for Periprosthetic
Joint Infection
Variable Odds Ratio* P Value
Age 1.1 (1.0 to 1.1) 0.001
Male sex 2.3 (1.0 to 5.3) 0.05
Knee joint involved 1.5 (0.6 to 3.6) 0.35
No. of procedures
In ninety days 2.5 (0.9 to 7.0) 0.09
In one year 0.3 (0.1 to 0.8) 0.01
Charlson Comorbidity Index 1.6 (1.2 to 2.1) 0.001
Ethnicity
Black (versus white) 1.5 (0.4 to 6.4) 0.56
Other (versus white) 0.6 (0.0 to 14.6) 0.74
Unknown (versus white) 2.2 (0.5 to 9.2) 0.27
Comorbidities
Diabetes 0.5 (0.2 to 1.3) 0.15
Cardiac disease 2.7 (1.1 to 6.3) 0.03
Chronic obstructive
pulmonary disease
2.5 (0.9 to 7.0) 0.09
Gastrointestinal disorders 2.8 (0.5 to 15.3) 0.23
History of cerebrovascular
accident
3.6 (1.0 to 12.7) 0.05
Renal disease 0.0 (0.0 to 0.0) 1.0
BMI 1.0 (1.0 to 1.1) 0.48
Infecting organism
Gram-positive 0.1 (0.0 to 1.2) 0.06
Staphylococcus 1.7 (0.0 to 75.3) 0.78
Methicillin-sensitive
S. aureus
1.1 (0.1 to 21.4) 0.97
Methicillin-resistant
S. aureus
1.5 (0.1 to 5.3) 0.79
Coagulase-negative
Staphylococcus
0.7 (0.0 to 14.3) 0.84
Streptococcus 1.1 (0.1 to 10.8) 0.97
Gram-negative 0.3 (0.0 to 2.9) 0.31
Polymicrobial 6.3 (1.3 to 30.8) 0.02
Culture-negative 0.1 (0.0 to 1.4) 0.09
*The values are given as the odds ratio, with the 95% confidence
interval in parentheses.
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health, suggesting another mechanism by which polymicrobial
infections predispose to early death. Gram-negative infections
are also expected to be associated with poor overall health. This
is evident in an analysis of success in treating gram-negative
periprosthetic joint infection at this institution, where the
current authors (B.Z. and J.P.) found that a large proportion of
patients (26% [six of twenty-three]) did not complete a two-
stage exchange because of death53. Lastly, MRSA is a particularly
virulent organism that can cause persistent periprosthetic joint
infection and increased cost of treatment49,53,56. Evidence provided
by Nixon et al. demonstrated that, following femoral fracture
and admission to an orthopaedic ward, infection with MRSA
doubled the risk of first-year mortality31. Similarly, Leung et al.
reported that 24% of patients receiving treatment for peri-
prosthetic joint infection due to MRSA had died at a mean
follow-up of nearly five years54. The current study also found a
trend of MRSA predicting mortality, and MRSA has once again
been proven to predict a dismal outcome.
The limitations of this study included its retrospective
nature and reliance upon an electronic database to identify pa-
tients and other factors investigated. However, the Social Se-
curity Death Index has been validated as a tool for identifying
deceased patients57. In attempts to mitigate the inaccuracy of
periprosthetic joint infection classification, all periprosthetic
joint infection cases were confirmed with use of a stringent and
recently proposed standard definition for periprosthetic joint
infection36. However, because not all variables were available for
this analysis, it was necessary to eliminate the cases that could
not be confirmed, limiting our study cohort and likely elimi-
nating some cases of true periprosthetic joint infection that had
negative cultures. Furthermore, this definition cannot be used
in patients not requiring surgical intervention as it includes
tissue specimen for culture, joint appearance, and histological
analysis in its defining criteria. Thus, this analysis is limited
to only the patients with periprosthetic joint infection who
underwent surgical treatment. Additionally, operative variables
such as operative time and blood loss were not reliably available
for the entire cohort and were not reported. However, we do not
believe that this weakens the findings, as the mortality rate of
patients with periprosthetic joint infection was no different
in the early postoperative period (thirty days) compared with
the control group. Attempts were made to determine whether
periprosthetic joint infection is an independent predictor of
mortality by controlling for age, sex, ethnicity, number of
surgical procedures, involved joint, BMI, and Charlson Comor-
bidity Index. Although it is believed that this adjustment suffi-
ciently accounts for differences between the cohorts, it is not
possible to identify all potential predictors of mortality that may
vary between the groups.
In conclusion, undergoing treatment for periprosthetic
joint infection significantly and independently increases the
risk of mortality. It is evident that increased risk of mortality is
due to a direct adverse effect of periprosthetic joint infection, as
well as the fact that periprosthetic joint infection is a reflection
of a decreased health status. Thus, in addition to the many
efforts invested to control infection in patients diagnosed with
periprosthetic joint infection, it is paramount to also ensure a
tight control of the chronic diseases.
Appendix
A table comparing the infecting organism between pa-
tients who died and those who survived the first year fol-
lowing treatment is available with the online version of this article
as a data supplement at jbjs.org. n
NOTE: We are grateful to Mitchell Maltenfort, PhD, for his assistance with statistical analysis.
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